Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine
作者:David W. Robertson、E. E. Beedle、Joseph H. Krushinski、G. Don Pollock、Harve Wilson、Virginia L. Wyss、J. Scott Hayes
DOI:10.1021/jm00383a006
日期:1985.6
2-phenylimidazo[4,5-b]pyridines (e.g., sulmazole) or 8-phenylpurines. Furthermore, all imidazo[4,5-c]pyridine analogues we tested were orally active; in contrast, only one of the imidazo[4,5-b]pyridine derivatives, sulmazole, was significantly active. One of several highly active compounds in the [4,5-c] series was 50 (LY175326, 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine hydrochloride)
最近,已经发现几种在实验动物和人体内具有正性和血管扩张活性的非儿茶酚胺,非糖苷强心药。原型化合物包括氨力农,舒马唑和芬诺酮。我们研究了一系列含有稠合到2-苯基咪唑的杂环的分子中最佳肌力活性所需的结构要求,发现2-苯基咪唑并[4,5-c]吡啶的效力通常比类似的2强5-10倍-苯基咪唑并[4,5-b]吡啶(例如,舒马唑)或8-苯基嘌呤。此外,我们测试的所有咪唑并[4,5-c]吡啶类似物均具有口服活性。相反,只有咪唑并[4,5-b]吡啶衍生物之一舒马唑具有明显的活性。[4,5-c]系列中几种高活性化合物之一是50(LY175326,2- [2-甲氧基-4-(甲基亚磺酰基)苯基] -1H-咪唑并[4,5-c]吡啶盐酸盐)。介绍了该系列的结构活性关系,并将其与咪唑并[4,5-b]吡啶和嘌呤系列进行了比较。